Evidence map›Paper›PMID 42368403›Full record

ArticleInternational journal of nanomedicine2026

PEG-NH

Xiangping Luo, Xiaochun Jiang, Zheng Kang

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xiangping LuoDepartment of Orthopaedics, Affiliated Hengyang Hospital of Hunan Normal University & Hengyang Central Hospital, Hengyang, Hunan, 421001, People's Republic of China.
Xiaochun JiangDepartment of Orthopaedics, Affiliated Hengyang Hospital of Hunan Normal University & Hengyang Central Hospital, Hengyang, Hunan, 421001, People's Republic of China.
Zheng KangDepartment of Orthopaedics, Affiliated Hengyang Hospital of Hunan Normal University & Hengyang Central Hospital, Hengyang, Hunan, 421001, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Osteoarthritis is a prevalent disease that causes pain and disability in older adults. MicroRNA-140 (miR-140) emerges as a promising therapeutic agent as it suppresses cartilage-degrading enzymes (eg, ADAMTS5, MMPs). However, its clinical translation is limited by rapid intra-articular degradation and poor chondrocyte penetration. The purpose of this experiment was to construct a nanocarrier for delivering miR-140 into chondrocytes, and to detect its delivery efficiency and biological effects. Methods: We engineered polyethylene glycol-aminated gold nanoparticles (AuNPs-PEG-NH Results: Fluorescence microscopy and flow cytometry revealed efficient delivery of miR-140-5p into ATDC5 cells by AuNPs-PEG-NH Conclusion: AuNPs-PEG-NH

Indexed as

GoldMetal NanoparticlesMicroRNAsOsteoarthritisPolyethylene GlycolsADAMTS5 ProteinAnimalsCell LineChondrocytesDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLADAMTS5 ProteinGoldMicroRNAsMIRN140 microRNA, mousePolyethylene Glycolscartilagegold nanoparticlesmicroRNAosteoarthritis

Identifiers

PMID42368403
PMCPMC13310059

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.